Provider Briefing: Calcipotriene Supply and Access in 2026

If your patients have been reporting difficulty filling their Calcipotriene prescriptions, the anecdotal evidence aligns with a broader pattern. While Calcipotriene (Calcipotriol) is not currently listed on the FDA's official drug shortage database, intermittent supply disruptions at the pharmacy level have made this topical Vitamin D3 analogue harder to obtain in many markets.

This guide summarizes the current state of Calcipotriene availability, the factors driving access challenges, and actionable strategies you can implement in your practice to minimize treatment disruptions for your psoriasis patients.

Timeline: How We Got Here

Calcipotriene has been a mainstay of topical psoriasis management since the FDA approved Dovonex in the mid-1990s. Over the past decade, several developments have shaped its availability:

• Patent expiration and generic entry: As patents on branded Dovonex and Sorilux expired, generic manufacturers entered the market, bringing prices down but also creating a dependency on a small number of producers.
• Manufacturer consolidation: The generic topical market has seen significant consolidation, with fewer companies producing a broader range of dermatological products. This concentration increases vulnerability to single-point supply failures.
• Intermittent production gaps: Beginning in 2023-2024, some generic Calcipotriene manufacturers experienced production pauses related to facility inspections, raw material sourcing, and quality assurance processes. While none triggered an official FDA shortage designation, the cumulative effect has been inconsistent pharmacy-level stock.
• 2025-2026 stabilization: Supply has generally improved heading into 2026, though spot shortages continue to be reported, particularly for the cream and ointment formulations.

Prescribing Implications

For dermatologists and primary care providers managing psoriasis patients on Calcipotriene, the current environment raises several practical considerations:

Formulation Flexibility

Calcipotriene is available in four formulations — cream, ointment, foam, and scalp solution — all at 0.005%. When prescribing, consider the following:

• Specify "may substitute formulation" or write prescriptions for multiple formulations to give the pharmacy flexibility
• Educate patients that all four forms contain the same active ingredient and have comparable efficacy
• The foam (Sorilux) may have different availability than the cream/ointment — checking with pharmacy prior to prescribing can save the patient a trip

Combination Products

Calcipotriene/Betamethasone Dipropionate combinations (Taclonex ointment, Enstilar foam) may be more readily available than standalone Calcipotriene in some markets. For patients who need Calcipotriene and are appropriate candidates for adjunctive corticosteroid therapy, the combination product can serve as a bridge during supply gaps.

Keep in mind that the steroid component makes these less suitable for long-term maintenance or use in sensitive areas (face, intertriginous zones) compared to standalone Calcipotriene.

Alternative Agents

When Calcipotriene is truly unavailable, consider these alternatives based on the patient's clinical profile:

• Tazarotene (Tazorac): Topical retinoid with good evidence for plaque psoriasis. Generic widely available. Note: Pregnancy Category X.
• Tapinarof (Vtama): AhR agonist approved for adult plaque psoriasis. Non-steroidal, steroid-sparing, but brand-only with higher cost.
• Roflumilast cream (Zoryve): Topical PDE4 inhibitor. Non-steroidal option with FDA approval for plaque psoriasis.
• Coal tar preparations: OTC option for mild disease or as adjunctive therapy. Lower efficacy than prescription agents.

Current Availability Picture

The national availability of Calcipotriene varies by formulation, region, and pharmacy chain. Key observations:

• Large chain pharmacies may not stock Calcipotriene routinely at all locations, leading to order-on-demand delays of 1-5 business days
• Independent pharmacies with relationships across multiple wholesalers often have better real-time access
• Mail-order pharmacies typically maintain more consistent stock for dermatological specialty products
• Regional variation exists — metro areas generally have better availability than rural regions

Cost and Access Considerations

Cost remains a significant factor in patient adherence to Calcipotriene:

• Cash price: $200-$460 for a 60g tube of generic cream at retail
• With discount cards: $45-$70 through GoodRx, SingleCare, or similar programs
• Insurance coverage: Generic Calcipotriene is on most formularies, but prior authorization may be required for brand-name products. Copays typically range from $10-$50.
• Patient assistance: No manufacturer savings program currently exists for generic Calcipotriene, though discount card programs substantially reduce out-of-pocket costs for uninsured patients

When patients report cost as a barrier, directing them to discount programs can be as impactful as changing medications. A resource like our Calcipotriene savings guide provides specific options.

Tools and Resources for Your Practice

Several tools can help you and your staff manage Calcipotriene access challenges more efficiently:

Pharmacy Stock Verification

Medfinder for Providers allows you to check real-time pharmacy stock by medication and location. This can be integrated into your prescribing workflow — verify availability before the patient leaves the office, reducing failed fill attempts.

Patient Education

Proactively educate patients about potential access challenges and equip them with resources:

• Direct patients to medfinder.com/providers for pharmacy stock checks
• Encourage early refills (1-2 weeks before running out)
• Discuss formulation flexibility upfront
• Provide information about discount programs for uninsured patients

Electronic Prescribing Tips

• Consider adding notes in the e-prescribe system allowing pharmacist to substitute formulation (cream ↔ ointment) when one is unavailable
• If your EHR supports it, flag Calcipotriene prescriptions for a follow-up check to ensure the patient filled successfully

Looking Ahead

The topical psoriasis treatment landscape continues to expand, which should ease some of the pressure on Calcipotriene supply:

• New non-steroidal agents (Tapinarof, Roflumilast) provide clinically meaningful alternatives
• Generic competition for combination products (Calcipotriene/Betamethasone) is increasing, which may improve both availability and pricing
• The FDA's ongoing efforts to encourage generic drug manufacturing and reduce supply chain vulnerabilities may have long-term benefits for niche dermatological products

In the meantime, a flexible prescribing approach that accounts for real-world availability — combined with proactive patient education — remains the most effective strategy.

Final Thoughts

Calcipotriene remains an excellent first-line non-steroidal topical for plaque psoriasis. The current access challenges, while frustrating, are manageable with a proactive approach. By building formulation flexibility into your prescribing, staying informed about supply trends, and leveraging tools like Medfinder for Providers, you can help ensure your patients maintain continuity of care.

For the patient-facing version of this update, see Calcipotriene Shortage Update: What Patients Need to Know in 2026.